PainReform (NASDAQ:PRFX – Get Free Report) and Harmony Biosciences (NASDAQ:HRMY – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.
Profitability
This table compares PainReform and Harmony Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PainReform | N/A | N/A | N/A |
| Harmony Biosciences | 18.88% | 20.06% | 14.15% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for PainReform and Harmony Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PainReform | 1 | 0 | 0 | 0 | 1.00 |
| Harmony Biosciences | 1 | 5 | 5 | 0 | 2.36 |
Volatility & Risk
PainReform has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500.
Institutional and Insider Ownership
37.3% of PainReform shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 34.4% of PainReform shares are owned by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares PainReform and Harmony Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| PainReform | $31,000.00 | 25.03 | -$5.02 million | ($736.66) | -0.00 |
| Harmony Biosciences | $959.90 million | 2.39 | $158.69 million | $3.08 | 12.78 |
Harmony Biosciences has higher revenue and earnings than PainReform. PainReform is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Harmony Biosciences beats PainReform on 11 of the 14 factors compared between the two stocks.
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.
About Harmony Biosciences
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.
